Основная статистика
| LEI | 529900NVAFLKA00F3U05 |
| CIK | 875657 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ultralife Corporation
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2025 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employ |
|
| August 27, 2025 |
Exhibit 16.1 August 25, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549-7561 Dear Sirs: We have read Ultralife Corporation’s statements included under Item 4.01 of its Form 8-K dated August 22, 2025, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K. Sincerely, /s/ Freed Maxick, P.C. Freed Max |
|
| August 7, 2025 |
Ultralife Corporation Reports Second Quarter Results Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 7, 2025 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2025 with the following results: ● Sales of $48.6 million increased 13.0% from $43.0 million for the second quarter of 2024; excluding Electrochem, sales of $39.3 million declined 8.7% due to a 57.2% |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 7, 2025 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CO |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 16, 2025 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-210-6110 (Nam |
|
| May 28, 2025 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2024 to December 31, 2024 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2024 to December 31, 2024, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ☒ Definitive Proxy Statement (as permitted |
|
| May 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ☐ Definitive Proxy Statement (as permitted |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE C |
|
| May 9, 2025 |
Ultralife Corporation Reports First Quarter Results Exhibit 99.1 Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. – May 9, 2025 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2025 with the following highlights: ● Sales of $50.7 million compared to $41.9 million for the 2024 first quarter, including a 32.4% increase for Batteries & Energy Products and a 36.2% decrease in Commun |
|
| May 9, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 9, 2025 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer I |
|
| April 28, 2025 |
Ultralife Corporation Insider Trading Compliance Policy Exhibit 97.2 ULTRALIFE CORPORATION INSIDER TRADING COMPLIANCE POLICY Summary Federal Securities Laws prohibit persons from purchasing or selling the securities of a company when they are in possession of material non-public information about the company. A person who purchases or sells the securities of a company when in possession of material non-public information about that company is guilty of |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-208 |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPOR |
|
| April 1, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 1, 2025 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| April 1, 2025 |
Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in ABLE New Energy Co., Limited, incorporated in Hong Kong, which has a 100% ownership interest in ABLE New Energy Co., Ltd, incorporated in the People’s Republic of China. We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom. Through our ownership interest in Ultralife UK LTD, we have a 100% |
|
| April 1, 2025 |
Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results Acquisition of Electrochem Completed and Integration Has Commenced NEWARK, N.Y. – April 1, 2025 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2024 as follows: Fourth Quarter: ● Sales of $43.9 million compared to $44.5 million for the 2023 fourth quarter, inc |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☒Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition Report on Form 10-K For the Transition Period E |
|
| January 16, 2025 |
UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION Exhibit 99.4 UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION On October 31, 2024, Ultralife Corporation, a Delaware corporation (“Ultralife” or the “Company”), completed the acquisition of all the issued and outstanding shares of Electrochem Solutions, Inc., a Massachusetts corporation (“Electrochem”) for $48.0 million in cash (the “Acquisition”). The unaudited pro forma combined statements of |
|
| January 16, 2025 |
Exhibit 99.2 Electrochem Solutions, Inc. (A Carve-Out Business of Integer Holdings Corp.) Combined Financial Statements As of and for the year ended December 31, 2023 Table of Contents Report of Independent Auditors i Combined Balance Sheet 1 Combined Statement of Operations 2 Combined Statement of Changes in Parent Equity 3 Combined Statement of Cash Flow 4 Notes to the Combined Financial Stateme |
|
| January 16, 2025 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission Fil |
|
| January 16, 2025 |
Exhibit 99.3 Electrochem Solutions, Inc. (A Carve-Out Business of Integer Holdings Corp.) Unaudited Combined Financial Statements As of and for the nine-month period ended September 27, 2024 Table of Contents Combined Balance Sheet 1 Combined Statement of Operations 2 Combined Statement of Changes in Parent Equity 3 Combined Statement of Cash Flow 4 Notes to the Combined Financial Statements 5 Ele |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALI |
|
| November 8, 2024 |
Ultralife Corporation Reports Third Quarter Results Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – November 8, 2024 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2024 as follows: ● Sales of $35.7 million compared to $39.5 million for the 2023 third quarter, including 1.9% growth in Battery & Energy Products sales and a 58.2% decrease in Communications Sys |
|
| November 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 8, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| November 6, 2024 |
Supply Agreement dated as of October 31, 2024 ** Exhibit 10.4 SUPPLY AGREEMENT This SUPPLY AGREEMENT (the “Agreement”), dated as of October 31, 2024 (the “Effective Date”), is made by and between Greatbatch Ltd., a New York corporation (“Greatbatch”), and Electrochem Solutions, Inc., a Massachusetts corporation (“Customer” together with Greatbatch, the “Parties” and each a “Party”). Capitalized terms used and not otherwise defined herein have th |
|
| November 6, 2024 |
Credit and Security Agreement dated as of October 31, 2024 Exhibit 10.2 CREDIT AND SECURITY AGREEMENT among ULTRALIFE CORPORATION SOUTHWEST ELECTRONIC ENERGY CORPORATION - AN ULTRALIFE COMPANY CLB, INC. EXCELL BATTERY CORPORATION USA ELECTROCHEM SOLUTIONS, INC. as Borrowers THE LENDERS NAMED HEREIN as Lenders and KEYBANK NATIONAL ASSOCIATION as Administrative Agent, Swing Line Lender and Issuing Lender KEYBANC CAPITAL MARKETS INC. as Lead Arranger and Sol |
|
| November 6, 2024 |
Ultralife Corporation Completes Acquisition of Electrochem Solutions, Inc. Exhibit 99.1 Company Contact: Ultralife Corporation Philip A. Fain (315) 210-6110 [email protected] Investor Relations Contact: LHA Jody Burfening (212) 838-3777 [email protected] Ultralife Corporation Completes Acquisition of Electrochem Solutions, Inc. NEWARK, N.Y. – November 1, 2024 - Ultralife Corporation (NASDAQ: ULBI) completed its acquisition of all outstanding shares of Electrochem Solution |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| November 6, 2024 |
Transition Services Agreement dated as of October 31, 2024 ** Exhibit 10.5 TRANSITION SERVICES AGREEMENT This TRANSITION SERVICES AGREEMENT (this “Agreement”), dated as of October 31, 2024 (the “Effective Date”), is made by and among Greatbatch Ltd., a New York corporation (“Seller”), Ultralife Corporation, a Delaware corporation (“Buyer”) and Electrochem Solutions, Inc., a Massachusetts corporation (the “Company”, together with Seller and Buyer, each a “Par |
|
| November 6, 2024 |
Assignment and Assumption Agreement dated as of October 31, 2024 ** Exhibit 10.3 ASSIGNMENT AND ASSUMPTION AGREEMENT THIS ASSIGNMENT AND ASSUMPTION AGREEMENT, dated as of October 31, 2024 (this “Assignment and Assumption Agreement”), is entered into by and among, Integer Holdings Corporation, a Delaware corporation (“Integer”) and Greatbatch Ltd., a New York corporation (“Seller,” and each Integer and Seller, an “Assignor”), and Electrochem Solutions, Inc., a Mass |
|
| October 3, 2024 |
Stock Purchase Agreement dated September 27, 2024 Exhibit 10.1 Execution Version STOCK PURCHASE AGREEMENT by and between GREATBATCH LTD. as Seller and ULTRALIFE CORPORATION as Buyer dated as of September 27, 2024 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 ARTICLE II PURCHASE AND SALE 13 Section 2.01. Purchase and Sale of the Shares 13 Section 2.02. Purchase Price 13 Section 2.03. Closing Date Payment; Purchase Price Adjustments 13 Section 2.0 |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emp |
|
| October 3, 2024 |
Exhibit 99.1 Ultralife Corporation to Acquire Electrochem Solutions, Inc. Acquisition to Drive Profitability through Increased Scale and Achievable Opportunities for Gross Margin Expansion NEWARK, N.Y. – September 30, 2024 - Ultralife Corporation (NASDAQ: ULBI) has signed a stock purchase agreement to acquire all outstanding shares of Electrochem Solutions, Inc. (“Electrochem”) to include its stat |
|
| July 25, 2024 |
Exhibit 10.1 FOURTH AMENDMENT AGREEMENT This Fourth Amendment Agreement (this “Agreement”) is made and entered into as of this [] day of June, 2024, by and among ULTRALIFE CORPORATION, a Delaware corporation (“Ultralife”), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (“Southwest”), CLB, INC., a Texas corporation (“CLB”), ULTRALIFE EXCELL HOLDING CORP., a Delaware corporation (“UEHC |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CO |
|
| July 25, 2024 |
Ultralife Corporation Reports Second Quarter Results Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – July 25, 2024 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2024 with the following highlights: ● Sales of $43.0 million compared to $42.7 million for the 2023 second quarter, including 8.3% growth in Battery & Energy Products sales to its highest level in the |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 25, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 17, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 16, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| May 30, 2024 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2023 to December 31, 2023 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2023 to December 31, 2023, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-210-6110 (Nam |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☐ Definitive Proxy Statement permitted |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ☒ Definitive Proxy Statement (as permitted |
|
| May 3, 2024 |
VIA EDGAR May 3, 2024 Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N. |
|
| May 2, 2024 |
As filed with the Securities and Exchange Commission on May 2, 2024 As filed with the Securities and Exchange Commission on May 2, 2024 Registration No. |
|
| April 26, 2024 |
-12-31FY2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| April 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 25, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE C |
|
| April 25, 2024 |
Ultralife Corporation Reports First Quarter Results Exhibit 99.1 Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. – April 25, 2024 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the first quarter ended March 31, 2024 with the following highlights: ● Sales of $41.9 million representing a 31.4% year-over-year increase, including 54.7% growth in medical market sales ● Gross profit of $11.5 million, or 27.4% of re |
|
| March 29, 2024 |
Calculation of Filing Fees table ** EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Ultralife Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(1) Maximum Aggregate Offering Price(1) Fee Rate Amount of Registrat |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 28, 2024 As filed with the Securities and Exchange Commission on March 28, 2024 Registration No. |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPOR |
|
| March 21, 2024 |
Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in ABLE New Energy Co., Limited, incorporated in Hong Kong, which has a 100% ownership interest in ABLE New Energy Co., Ltd, incorporated in the People’s Republic of China. Through our ownership interest in Ultralife UK LTD, we have a 100% controlling interest in Accutronics, Ltd., also incorporated in the United Kingdom. We have a 100% own |
|
| March 21, 2024 |
Ultralife Corporation Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97.1 ULTRALIFE CORPORATION POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION BACKGROUND NASDAQ’s new rule, “NASDAQ Listing Rule 5608”, requires all listed U.S. companies to adopt clawback policies. A company’s clawback policy must require it to recover, reasonably promptly, erroneously awarded incentive based compensation to a Section 16 reporting officer during the performance p |
|
| February 15, 2024 |
Ultralife Corporation Reports Fourth Quarter Results Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. – February 15, 2024 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the fourth quarter and full year ended December 31, 2023. Fourth Quarter Highlights: ● Sales of $44.5 million representing a 23.4% year-over-year increase ● Highest medical sales quarter in Company’s history ● Operating income of $ |
|
| February 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 15, 2024 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| February 9, 2024 |
ULBI / Ultralife Corporation / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8 )* Ultralife Corp (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| October 26, 2023 |
Ultralife Corporation Reports Third Quarter Results Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – October 26, 2023 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the third quarter ended September 30, 2023 with the following highlights: ● Sales of $39.5 million representing an 18.8% year-over-year increase ● Operating income of $2.1 million versus a loss of $0.6 million for the 2022 third quar |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALI |
|
| October 26, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 26, 2023 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| July 27, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 27, 2023 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 27, 2023 |
Ultralife Corporation Reports Second Quarter Results Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – July 27, 2023 - Ultralife Corporation (NASDAQ: ULBI) reported operating results for the second quarter ended June 30, 2023 with the following highlights: ● Sales of $42.7 million representing a 32.9% year-over-year increase ● Operating income of $3.7 million compared to $0.8 million for the 2022 second quarter ● Adjus |
|
| July 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:0-20852 ULTRALIFE COR |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 19, 2023 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| May 31, 2023 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2022 to December 31, 2022 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2022 to December 31, 2022, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-210-6110 (Nam |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☐ Definitive Proxy Statement permitted |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ☒ Definitive Proxy Statement (as permitted |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number:0-20852 ULTRALIFE CO |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 -12-31FY2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| April 27, 2023 |
Ultralife Corporation Reports First Quarter Results Exhibit 99.1 Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. – April 27, 2023 - Ultralife Corporation (NASDAQ: ULBI) reported breakeven operating income and adjusted EBITDA of $1.2 million on revenue of $31.9 million for the first quarter ended March 31, 2023. The operating results for the first quarter of 2023 were negatively impacted by the cybersecurity attack announced by the |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2023 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| March 31, 2023 |
Exhibit 10.8 THIRD AMENDMENT AGREEMENT This Third Amendment Agreement (this “Agreement”) is made and entered into as of this 28th day of November, 2022, by and among ULTRALIFE CORPORATION, a Delaware corporation (“Ultralife”), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (“Southwest”), CLB, INC., a Texas corporation (“CLB”), ULTRALIFE EXCELL HOLDING CORP., a Delaware corporation (“ |
|
| March 31, 2023 |
Youâve Exceeded the SECâs Traffic Limit Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in ABLE New Energy Co., Limited, incorporated in Hong Kong, which has a 100% ownership interest in ABLE New Energy Co., Ltd, incorporated in the People’s Republic of China. Through our ownership interest in Ultralife UK LTD, we have a 100% controlling interest in Accutronics, Ltd., also incorporated in the United Kingdom. We have a 100% own |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPOR |
|
| March 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 2, 2023 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| March 2, 2023 |
Ultralife Corporation Reports Fourth Quarter Results Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. – March 2, 2023 - Ultralife Corporation (NASDAQ: ULBI) reported operating profit of $0.2 million and adjusted EBITDA of $2.0 million on revenue of $36.1 million for the fourth quarter ended December 31, 2022. The operating results for the fourth quarter of 2022 include a one-time charge of $0.8 million for 2023 severanc |
|
| February 22, 2023 |
Ultralife Corporation Adds Janie Goddard to its Board of Directors Exhibit 99.1 Ultralife Corporation Adds Janie Goddard to its Board of Directors NEWARK, N.Y. February 22, 2023 – Ultralife Corporation (NASDAQ: ULBI) announced today the addition of Janie Goddard as Director of the Company. Chairman Bradford Whitmore said, “We are pleased to welcome Janie to our Board of Directors and look forward to leveraging her extensive business career. Janie is an experience |
|
| February 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2023 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| February 10, 2023 |
ULBI / Ultralife Corp. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7 )* Ultralife Corp (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 22, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| November 22, 2022 |
Ultralife Corporation Names Michael E. Manna President & CEO Exhibit 99.1 Ultralife Corporation Names Michael E. Manna President & CEO NEWARK, N.Y. November 22, 2022 ? The Board of Directors of Ultralife Corporation (?Ultralife? or the ?Company?) (NASDAQ: ULBI) has appointed Michael E. Manna as the Company?s President & CEO and as a member of the Board of Directors effective immediately to replace Michael D. Popielec who is leaving the Company. Mr. Popielec |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 27, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| October 27, 2022 |
Ultralife Corporation Receives $5.5 Million Communications Systems Contract Exhibit 99.1 Ultralife Corporation Receives $5.5 Million Communications Systems Contract NEWARK, N.Y. October 27, 2022 - Ultralife Corporation (NASDAQ: ULBI) has been awarded a purchase order valued at approximately $5.5 million to supply its vehicle communications systems to a global prime defense contractor for the U.S. Army. Ultralife’s vehicle communications platform provides the soldier with |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 27, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| October 27, 2022 |
Ultralife Corporation Reports Third Quarter Results Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – October 27, 2022 - Ultralife Corporation (NASDAQ: ULBI) reported an operating loss of $0.6 million and adjusted EBITDA of $1.3 million on revenue of $33.2 million for the third quarter ended September 30, 2022. For the third quarter of 2021, the Company reported an operating loss of $0.8 million and adjusted EBITDA of |
|
| October 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALI |
|
| September 22, 2022 |
Ultralife Corporation Receives $7.5 Million Communications Systems Contract Exhibit 99.1 Ultralife Corporation Receives $7.5 Million Communications Systems Contract NEWARK, N.Y. September 22, 2022 - Ultralife Corporation (NASDAQ: ULBI) has received a contract valued at approximately $7.5 million to supply its integrated system of A-320 amplifiers and A-320HVA radio vehicle mounts to a major international defense contractor for an ongoing government/defense modernization p |
|
| September 22, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 22, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emp |
|
| July 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CO |
|
| July 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 28, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 28, 2022 |
Ultralife Corporation Reports Second Quarter Results Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. ? July 28, 2022 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $0.8 million and Adjusted EBITDA of $2.2 million on revenue of $32.1 million for the second quarter ended June 30, 2022. For the second quarter of 2021, the Company reported operating income of $1.1 million and Adjusted EBITDA of $2.2 mi |
|
| July 26, 2022 |
Ultralife Corporation Awarded $4.6 Million Communications Systems Vehicle Amplifier-Adaptor Order Exhibit 99.1 Ultralife Corporation Awarded $4.6 Million Communications Systems Vehicle Amplifier-Adaptor Order NEWARK, N.Y. July 26, 2022 - Ultralife Corporation (NASDAQ: ULBI) has been awarded a purchase order valued at approximately $4.6 million to supply its Vehicle Amplifier-Adaptors (?VAA?) to a global prime defense contractor. Ultralife?s VAA platform provides the soldier with an enhanced ra |
|
| July 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 26, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 20, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only ? Definitive Proxy Statement (as permitted |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as ? Definitive Proxy Statement permitted |
|
| May 31, 2022 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2021 to December 31, 2021 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2021 to December 31, 2021, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-210-6110 (Nam |
|
| April 28, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 2) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission Fi |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE C |
|
| April 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| April 28, 2022 |
Exhibit 99.2 Excell Battery Canada Inc. and 656700 BC Ltd. Combined Consolidated Financial Statements For the Period from February 1, 2021 to December 12, 2021 CONTENTS Page Independent Auditor?s Report 1 Combined Consolidated Balance Sheet 3 Combined Consolidated Statement of Income and Comprehensive Income 4 Combined Consolidated Statement of Changes in Stockholders? Equity 5 Combined Consolidat |
|
| April 28, 2022 |
Ultralife Corporation Reports First Quarter Results Exhibit 99.1 Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. ? April 28, 2022 - Ultralife Corporation (NASDAQ: ULBI) reported an operating loss of $0.3 million on revenue of $30.4 million for the first quarter ended March 31, 2022. For the first quarter of 2021, the Company reported operating income of $1.0 million on revenue of $26.0 million. ?Strong order flow in commercial end- |
|
| April 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 -12-31FY2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file |
|
| March 8, 2022 |
Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPOR |
|
| February 28, 2022 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission Fi |
|
| February 28, 2022 |
Exhibit 99.2 Excell Battery Canada Inc. and 656700 BC Ltd. Combined Consolidated Financial Statements For the Period from February 1, 2021 to December 12, 2021 CONTENTS Page Independent Auditor?s Report 1 Combined Consolidated Balance Sheet 3 Combined Consolidated Statement of Income and Comprehensive Income 4 Combined Consolidated Statement of Changes in Stockholders? Equity 5 Combined Consolidat |
|
| February 28, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on December 13, 2021, Ultralife Corporation (the ?Company?) completed its acquisition of all issued and outstanding shares of Excell Battery Canada Inc., a British Columbia corporation (?Excell Canada?), and 656700 B.C. Ltd., a British Columbia corporation (?656700?) and its wholly owned subsidiary E |
|
| February 8, 2022 |
ULBI / Ultralife Corp. / DIMENSIONAL FUND ADVISORS LP - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6 )* Ultralife Corp (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 3, 2022 |
Ultralife Corporation Reports Fourth Quarter Results Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. ? February 3, 2022 - Ultralife Corporation (NASDAQ: ULBI) reported an operating loss of $1.2 million on revenue of $23.8 million for the fourth quarter ended December 31, 2021. For the fourth quarter of 2020, the Company reported operating income of $1.2 million on revenue of $29.0 million. Included in the results for t |
|
| February 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 3, 2022 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| December 16, 2021 |
Exhibit 10.1 SECOND AMENDMENT AGREEMENT This Second Amendment Agreement (this ?Agreement?) is made and entered into as of this 13th day of December, 2021, by and among ULTRALIFE CORPORATION, a Delaware corporation (?Ultralife?), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (?Southwest?), CLB, INC., a Texas corporation (?CLB?, and together with Ultralife and Southwest, collectively, |
|
| December 16, 2021 |
Exhibit 10.4 TERM NOTE B $10,000,000.00 Newark, New York December , 2021 FOR VALUE RECEIVED, the undersigned, ULTRALIFE CORPORATION, a Delaware corporation (?Ultralife?), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (?Southwest?), CLB, INC., a Texas corporation (?CLB?), ULTRALIFE EXCELL HOLDING CORP., a Delaware corporation (?UEHC?), ULTRALIFE CANADA HOLDING CORP., a Delaware corpo |
|
| December 16, 2021 |
SHARE PURCHASE AGREEMENT By and Among 1336902 B.C. UNLIMITED LIABILITY COMPANY, as the Buyer And M. & W. HOLDINGS LTD., SANFORD CAPITAL LTD., IAN KANE, ARCEE ENTERPRISES INC., And 0835205 B.C. LTD., as the Sellers And MARK KROEKER, as the Sellers? Representative And 656700 B.C. LTD, as the Company Dated December 13, 2021 TABLE OF CONTENTS TABLE OF CONTENTS ii SHARE PURCHASE AGREEMENT 1 Article I - |
|
| December 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 13, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| December 16, 2021 |
Exhibit 10.2 PLEDGE AGREEMENT This Pledge Agreement, as it may be amended, restated or otherwise modified from time to time (this ?Agreement?), is executed and delivered as of the 13th day of December, 2021, by ULTRALIFE EXCELL HOLDING CORP., a Delaware corporation (?Pledgor?), to KEYBANK NATIONAL ASSOCIATION (together with its successors and assigns in its capacity as agent, ?Agent?), as agent fo |
|
| December 16, 2021 |
Exhibit 2.1 SHARE PURCHASE AGREEMENT By and Among 1336889 B.C. UNLIMITED LIABILITY COMPANY, as the Buyer And MARK KROEKER, RANDOLPH PETERS, BRIAN LARSEN, M. & W. HOLDINGS LTD., KAREN KROEKER HEATHER PETERSON, MICHAEL KROEKER, NICHOLAS KROEKER, BRENTLEY PETERS, CRAIG PETERS, KURTIS PETERS, HEATHER LARSEN, IAN KANE, CAROL PETERS And 0835205 B.C. LTD., as the Sellers And MARK KROEKER, as the Sellers? |
|
| December 16, 2021 |
Exhibit 99.1 Ultralife Corporation Acquires Excell Battery Group Advances Ultralife?s Commercial Revenue Diversification Strategy NEWARK, N.Y. ? December 14, 2021 - Ultralife Corporation (NASDAQ: ULBI) has acquired all of the outstanding shares of Excell Battery Group (?Excell?) for $23.5 million in cash, subject to customary working capital and net cash adjustments. Based in Canada with U.S. oper |
|
| December 16, 2021 |
Exhibit 10.3 ASSUMPTION AND JOINDER AGREEMENT, dated as of December [], 2021 (this ?Joinder?), is executed in connection with that certain SECOND AMENDMENT AGREEMENT dated as of the date hereof (the ?Second Amendment?) among ULTRALIFE CORPORATION, a Delaware corporation (?Ultralife?), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (?Southwest?), CLB, INC., a Texas corporation (?CLB?, |
|
| October 28, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 28, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| October 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALI |
|
| October 28, 2021 |
Ultralife Corporation Reports Third Quarter Results Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. ? October 28, 2021 - Ultralife Corporation (NASDAQ: ULBI) reported an operating loss of $0.8 million on revenue of $21.8 million for the third quarter ended September 30, 2021. For the third quarter of 2020, the Company reported operating income of $0.7 million on revenue of $24.4 million. ?Supply chain bottlenecks inten |
|
| July 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CO |
|
| July 29, 2021 |
Ultralife Corporation Reports Second Quarter Results Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. ? July 29, 2021 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.1 million on revenue of $26.8 million for the second quarter ended June 30, 2021. For the second quarter of 2020, the Company reported operating income of $2.3 million on revenue of $28.6 million. ?Ultralife?s end-market diversificati |
|
| July 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 29, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 23, 2021 |
As filed with the Securities and Exchange Commission on July 23, 2021 As filed with the Securities and Exchange Commission on July 23, 2021 Registration No. |
|
| July 23, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 21, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| June 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as ? Definitive Proxy Statement permitted |
|
| June 1, 2021 |
Amendment No. 1 to Ultralife Corporation Amended 2014 Long-Term Incentive Plan UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as ? Definitive Proxy Statement permitted |
|
| May 27, 2021 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2020 to December 31, 2020 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (?Report?) for the reporting period from January 1, 2020 to December 31, 2020, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-210-6110 (Nam |
|
| May 17, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 17, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| May 17, 2021 |
Exhibit 99.1 Ultralife Corporation Awarded IDIQ Contract Under U.S. Army?s $1.25B Conformal Wearable Battery Program NEWARK, N.Y. May 17, 2021 - Ultralife Corporation (NASDAQ: ULBI) has received a firm-fixed price indefinite-delivery/indefinite-quantity contract from the U.S. Army for purchases of Conformal Wearable Batteries not to exceed $168 million during the three-year base award period with |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE C |
|
| April 29, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 29, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| April 29, 2021 |
Ultralife Corporation Reports First Quarter Results EX-99.1 2 ex244515.htm EXHIBIT 99.1 Exhibit 99.1 Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. – April 29, 2021 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.0 million on revenue of $26.0 million for the first quarter ended March 31, 2021 compared to operating income of $1.5 million on revenue of $25.8 million for the first quarter of 2020. “Ultralife in |
|
| March 31, 2021 |
VIA EDGAR March 31, 2021 Securities and Exchange Commission Division of Corporation Finance Office of Manufacturing 100 F Street, N. |
|
| March 30, 2021 |
Common Stock, $.10 par value, contained in the Registrant’s Registration Statement on Form S-3 As filed with the Securities and Exchange Commission on March 30, 2021 Registration No. |
|
| March 26, 2021 |
-12-31 FY 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Ultralife Corp (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedul |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 4, 2021 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| February 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPOR |
|
| February 4, 2021 |
Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom. |
|
| February 4, 2021 |
Ultralife Corporation Reports Fourth Quarter Results Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. – February 4, 2021 - Ultralife Corporation (NASDAQ: ULBI) reported GAAP EPS of $0.13, Adjusted EPS of $0.17 and operating income of $1.2 million on revenue of $29.0 million for the fourth quarter ended December 31, 2020 compared to GAAP EPS of $0.10, Adjusted EPS of $0.13 and operating income of $2.5 million on revenue |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 29, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| October 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALI |
|
| October 29, 2020 |
Ultralife Corporation Reports Third Quarter Results Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – October 29, 2020 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $0.7 million on revenue of $24.4 million for the third quarter ended September 30, 2020. For the third quarter of 2019, the Company reported operating income of $1.3 million on revenue of $27.5 million. “Effective execution of both our |
|
| July 30, 2020 |
ULTRALIFE CORPORATION AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (Dollars in Thousands) Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – July 30, 2020 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.3 million on revenue of $28.6 million for the second quarter ended June 30, 2020. For the second quarter of 2019, the Company reported operating income of $3.0 million on revenue of $29.4 million. “Ultralife’s second quarter adjusted |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CO |
|
| July 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 30, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 23, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 23, 2020 (July 22, 2020) Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Numbe |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 7, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| July 7, 2020 |
Ultralife Corporation Announces Change in Location of Annual Meeting of Shareholders Exhibit 99.1 Ultralife Corporation Announces Change in Location of Annual Meeting of Shareholders NEWARK, N.Y. – July 7, 2020 - Ultralife Corporation (NASDAQ: ULBI) today announced that due to the ongoing public health impact of the coronavirus (COVID-19) pandemic and out of an abundance of caution, the location of the Annual Meeting of Shareholders to be held on July 22nd at 9:00 AM Eastern Time |
|
| July 7, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| June 29, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 29, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| June 29, 2020 |
Ultralife Corporation Announces Addition to the Russell 2000® Index Exhibit 99.1 Ultralife Corporation Announces Addition to the Russell 2000® Index NEWARK, N.Y. – June 29, 2020 - Ultralife Corporation (NASDAQ: ULBI) today announced it has been added to the Russell 2000® Index as part of the 2020 Russell U.S. Indexes annual reconstitution, effective as the U.S. market opens today. “Our inclusion in the Russell 2000® Index, one of the most widely used performance b |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☒ Definitive Proxy Statement permitted |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-332-7100 (Nam |
|
| June 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☐ Definitive Proxy Statement permitted |
|
| June 1, 2020 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2019 to December 31, 2019 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2019 to December 31, 2019, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE C |
|
| April 30, 2020 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. – April 30, 2020 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.5 million on revenue of $25.8 million for the first quarter ended March 31, 2020 compared to operating income of $0.5 million on revenue of $18.9 million for the first quarter of 2019. “Ultralife posted strong results for the first qu |
|
| April 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 30, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| April 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-208 |
|
| April 28, 2020 |
Description of Registrant’s Securities Exhibit 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Ultralife Corporation (the “Company”) has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) our Common Stock and (2) our Preferred Stock. DESCRIPTION OF CAPITAL STOCK The following is a descr |
|
| April 27, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 27, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| April 17, 2020 |
Exhibit 10.1 LOAN AGREEMENT * * * * * * * * * * THIS LOAN AGREEMENT (“Agreement”) is made on April 14, 2020, between the ULTRALIFE CORPORATION and KEYBANK NATIONAL ASSOCIATION identified in the SBA Approval issued by the U.S. Small Business Administration (“SBA”) to Lender, dated April 13, 2020 SBA Loan Number 57812171-01 (“Approval”). SBA has authorized a guaranty of a loan from Lender to Borrowe |
|
| April 17, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 14, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| April 17, 2020 |
Note, dated April 14, 2020 made by Ultralife Corporation Exhibit 10.2 U.S. Small Business Administration NOTE SBA Loan # 57812171-01 SBA Loan Name ULTRALIFE CORPORATION Date April 14, 2020 Loan Amount $3,459,278.00 Interest Rate 1.00% Borrower ULTRALIFE CORPORATION Operating Company N/A Lender KeyBank National Association 1. PROMISE TO PAY: In return for the Loan, Borrower promises to pay to the order of Lender the amount of $3,459,278.00 and 00/100 Dol |
|
| March 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 25, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| March 25, 2020 |
Exhibit 99.1 Ultralife Corporation Issues Letter to Stakeholders Regarding Business Operations in Response to COVID-19 NEWARK, N.Y. – March 25, 2020 - Ultralife Corporation (NASDAQ: ULBI) today issued a letter to its employees, customers, suppliers, and shareholders regarding its business operations amid the COVID-19 pandemic. The letter follows. As we continue to monitor the evolving impact of th |
|
| February 12, 2020 |
ULBI / Ultralife Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* ULTRALIFE CORP (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 6, 2020 |
Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom. |
|
| February 6, 2020 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. – February 6, 2020 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.5 million on revenue of $31.0 million for the fourth quarter ended December 31, 2019 compared to operating income of $1.1 million on revenue of $20.9 million for the fourth quarter of 2018. For fiscal 2019, Ultralife produced opera |
|
| February 6, 2020 |
ULBI / Ultralife Corp. 10-K - Annual Report - FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2019 OR ☐ Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CORPOR |
|
| February 6, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2020 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| December 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 18, 2019 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| December 18, 2019 |
Exhibit 99.1 Ultralife Corporation Receives Award for Its Legacy BA-5390 Military Batteries from Defense Logistics Agency NEWARK, N.Y. December 18, 2019 - Ultralife Corporation (NASDAQ: ULBI) has received a $4.9 million firm-fixed price delivery contract from the U.S. Government’s Defense Logistics Agency (DLA) for its lithium manganese dioxide, non-rechargeable BA-5390 batteries. Shipments are ex |
|
| October 31, 2019 |
ULBI / Ultralife Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALI |
|
| October 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2019 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emplo |
|
| October 31, 2019 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results NEWARK, N.Y. – October 31, 2019 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.3 million on revenue of $27.5 million for the third quarter ended September 29, 2019. For the third quarter of 2018, the Company reported operating income of $1.5 million on revenue of $20.3 million. “Third quarter revenue increased |
|
| September 26, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 23, 2019 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emp |
|
| September 19, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 18, 2019 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Emp |
|
| September 19, 2019 |
Exhibit 99.1 Ultralife Corporation Receives $14.4 Million IDIQ Award from Defense Logistics Agency for BA-5368 Military Batteries NEWARK, N.Y. September 19, 2019 - Ultralife Corporation (NASDAQ: ULBI) has received a firm-fixed price, indefinite-delivery/indefinite-quantity contract for purchases not to exceed $14.4 million from the U.S. Government’s Defense Logistics Agency (DLA) for its lithium m |
|
| August 1, 2019 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 1, 2019 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $3.0 million on revenue of $29.4 million for the second quarter ended June 30, 2019. For the second quarter of 2018, the Company reported operating income of $1.6 million on revenue of $22.9 million. Included in the results for the seco |
|
| August 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 1, 2019 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| August 1, 2019 |
ULBI / Ultralife Corp. 10-Q - Quarterly Report - FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE CO |
|
| July 25, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 25, 2019 (July 24, 2019) Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Numbe |
|
| July 15, 2019 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION As previously disclosed, on May 1, 2019, Ultralife Corporation (the “Company”) completed its acquisition of 100% of the issued and outstanding shares of Southwest Electronic Energy Corporation (“SWE”) for an aggregate purchase price of $25.0 million in cash, net of cash acquired and subject to customary post-closing working |
|
| July 15, 2019 |
EX-99.2 3 ex149425.htm EXHIBIT 99.2 Exhibit 99.2 Independent AuditorS’ Report To the Board of Directors and Stockholders of Southwest Electronic Energy Corporation Missouri City, Texas We have audited the accompanying consolidated financial statements of Southwest Electronic Energy Corporation (a Texas corporation), which comprise the consolidated balance sheet as of December 31, 2018, and the rel |
|
| July 15, 2019 |
Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 15, 2019 (May 1, 2019) Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Com |
|
| June 20, 2019 |
Ultralife Receives $10 Million Communications Systems IDIQ Contract Exhibit 99.1 Ultralife Receives $10 Million Communications Systems IDIQ Contract NEWARK, N.Y. June 20, 2019 - Ultralife Corporation (NASDAQ: ULBI) has received a fixed price, indefinite-delivery/indefinite-quantity contract for purchases not to exceed $9.986 million from the Naval Air Warfare Center Aircraft Division for our Universal Vehicle Adaptors (“UVA’s”) in support of the Family of Special |
|
| June 20, 2019 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 20, 2019 Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer |
|
| June 3, 2019 |
ULBI / Ultralife Corp. DEFA14A - - FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☐ Definitive Proxy Statement permitted |
|
| June 3, 2019 |
ULBI / Ultralife Corp. DEF 14A - - FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☒ Definitive Proxy Statement permitted |
|
| May 31, 2019 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2018 to December 31, 2018 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2018 to December 31, 2018, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 31, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-332-7100 (Nam |
|
| May 2, 2019 |
Exhibit 10.6 TERM NOTE $8,000,000 Newark, New York May 1, 2019 FOR VALUE RECEIVED, the undersigned, ULTRALIFE CORPORATION, a Delaware corporation (“Ultralife”), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (“Southwest”), CLB, INC., a Texas corporation (“CLB”), each other Person which may be added as a “Borrower” hereto, subsequent to the date hereof (collectively, together with Ult |
|
| May 2, 2019 |
Exhibit 10.2 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement, as it may be amended, restated or otherwise modified from time to time (this “Agreement”), is executed and delivered at Newark, New York as of this 1st day of May, 2019, by SOUTHWEST ELECTRONIC ENERGY CORPORATION, a corporation organized under the laws of the State of Texas (together with its succe |
|
| May 2, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 2, 2019 (May 1, 2019) Date of Report (Date of Earliest Event Reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) ( |
|
| May 2, 2019 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports First Quarter Results Acquires Southwest Electronic Energy Corporation for $25.0 Million NEWARK, N.Y. – May 2, 2019 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $0.5 million on revenue of $18.9 million for the first quarter ended March 31, 2019 compared to operating income of $2.4 million on revenue of $23.1 million for the first qu |
|
| May 2, 2019 |
Exhibit 10.1 Certain exhibits and schedules to this First Amendment Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. For a brief description of the contents of these omitted exhibits and schedules, refer to Omitted Exhibits and Schedules Disclosure List included as part of this Exhibit 10.1. The Company hereby undertakes to furnish supplementally a copy of any omitted exhi |
|
| May 2, 2019 |
Exhibit 10.3 INTELLECTUAL PROPERTY SECURITY AGREEMENT This Intellectual Property Security Agreement, as it may be amended, restated or otherwise modified from time to time (this “Agreement”), is executed and delivered at Newark, New York as of this 1st day of May 2019, by CLB, INC., a corporation organized under the laws of the State of Texas (together with its successors and assigns, “Pledgor”), |
|
| May 2, 2019 |
Exhibit 10.4 PLEDGE AGREEMENT This Pledge Agreement, as it may be amended, restated or otherwise modified from time to time (this “Agreement”), is executed and delivered as of the 1st day of May, 2019, by SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (“Pledgor”), to KEYBANK NATIONAL ASSOCIATION (together with its successors and assigns in its capacity as agent, “Agent”), as agent fo |
|
| May 2, 2019 |
Exhibit 10.5 ASSUMPTION AND JOINDER AGREEMENT, dated as of May 1, 2019 (this “Joinder”), is executed in connection with that certain FIRST AMENDMENT AGREEMENT dated as of the date hereof (the “First Amendment”) among ULTRALIFE CORPORATION, a Delaware corporation (“Existing Borrower”), SOUTHWEST ELECTRONIC ENERGY CORPORATION, a Texas corporation (“Southwest”), CLB, INC., a Texas corporation (“CLB”) |
|
| May 2, 2019 |
Exhibit 2.1 EXECUTION VERSION Certain exhibits and schedules to this Stock Purchase Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. For a brief description of the contents of these omitted exhibits and schedules, refer to Omitted Exhibits and Schedules Disclosure List included as part of this Exhibit 2.1. The Company hereby undertakes to furnish supplementally a copy of a |
|
| May 2, 2019 |
ULBI / Ultralife Corp. 10-Q Quarterly Report FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal quarter ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0-20852 ULTRALIFE COR |
|
| April 26, 2019 |
ULBI / Ultralife Corp. 10-K/A (Annual Report) FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 0-208 |
|
| March 18, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2019 Date of Report (Date of earliest event reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employe |
|
| February 15, 2019 |
ULBI / Ultralife Corp. FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) /X/ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 OR / / Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0 |
|
| February 8, 2019 |
ULBI / Ultralife Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* ULTRALIFE CORP (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 7, 2019 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports Fourth Quarter Results Net Income of $19.7 Million Includes $18.7 Million Tax Benefit NEWARK, N.Y. – February 7, 2019 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.1 million on revenue of $20.9 million for the fourth quarter ended December 31, 2018 compared to operating income of $2.1 million on revenue of $22.5 million for the fo |
|
| February 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 7, 2019 (Date of Report) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 Tec |
|
| February 7, 2019 |
ULBI / Ultralife Corp. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) /X/ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2018 OR / / Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0-20852 ULTRALIFE COR |
|
| February 7, 2019 |
Filed with Form 10-K for the year ended December 31, 2018, filed February 7, 2019 EX-21 2 ex133848.htm EXHIBIT 21 Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom. We have a 100% ownership interest in ABLE New Energy Co., Limited, incorporated in Hong Kong, which has a 100% ownership interest in ABLE New Energy Co., Ltd, incorporated in the People’s Republic of China. We have a 100% ownership interest |
|
| December 17, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 14, 2018 Date of Report (Date of earliest event reported) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| November 1, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2018 (Date of Report) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 Tec |
|
| November 1, 2018 |
ULTRALIFE CORPORATION AND SUBSIDIARIES Exhibit 99.1 Ultralife Corporation Reports Third Quarter Results Board of Directors Authorizes Share Repurchase Program NEWARK, N.Y. – November 1, 2018 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.5 million on revenue of $20.3 million for the third quarter ended September 30, 2018. For the third quarter of 2017, the Company reported operating income of $1.3 million on rev |
|
| November 1, 2018 |
ULBI / Ultralife Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended September 30, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27460 ULTRALIFE COR |
|
| October 25, 2018 |
Ultralife Receives $9.5 Million Communications Systems IDIQ Contract Exhibit 99.1 Ultralife Receives $9.5 Million Communications Systems IDIQ Contract NEWARK, N.Y. October 24, 2018 - Ultralife Corporation (NASDAQ: ULBI) has received a fixed price, indefinite-delivery/indefinite-quantity contract for purchases not to exceed $9.5 million from an undisclosed major defense prime contractor for vehicle communications kits for use by the U.S. Department of Defense. The a |
|
| October 25, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported) October 24, 2018 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS E |
|
| October 15, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported) October 15, 2018 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS E |
|
| October 15, 2018 |
Ultralife Corporation Awarded $8.3 Million Communications Systems Leader Radio Contract Exhibit 99.1 Ultralife Corporation Awarded $8.3 Million Communications Systems Leader Radio Contract NEWARK, N.Y. October 15, 2018 - Ultralife Corporation (NASDAQ: ULBI) has been awarded a contract valued at approximately $8.3 million to supply its Vehicle Amplifier-Adaptors (“VAA”) and Mounted VHF Amplifiers to Thales Defense & Security, Inc., a global leader in the development, manufacture, and |
|
| October 2, 2018 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported) October 2, 2018 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Em |
|
| October 2, 2018 |
Ultralife Corporation Awarded $10.9 Million Communications Systems Contract Exhibit 99.1 Ultralife Corporation Awarded $10.9 Million Communications Systems Contract NEWARK, N.Y. October 2, 2018 - Ultralife Corporation (NASDAQ: ULBI) has been awarded a contract valued at approximately $10.9 million to supply Vehicle Amplifier-Adaptors (“VAA’s”) and Mounted Power Amplifiers to Thales Defense & Security, Inc., a global leader in the development, manufacture, and support of c |
|
| August 2, 2018 |
Ultralife Corporation Reports Second Quarter Results Exhibit 99.1 Company Contact: Investor Relations Contact: Ultralife Corporation LHA Philip A. Fain Jody Burfening (315) 210-6110 (212) 838-3777 [email protected] [email protected] Ultralife Corporation Reports Second Quarter Results NEWARK, N.Y. – August 2, 2018 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $1.6 million on revenue of $22.9 million for the second quarter ended |
|
| August 2, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 2, 2018 (Date of Report) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 Techn |
|
| August 2, 2018 |
ULBI / Ultralife Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended July 1, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27460 ULTRALIFE CORPORATI |
|
| July 27, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported) July 25, 2018 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Empl |
|
| June 1, 2018 |
ULBI / Ultralife Corp. FORM DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as ☒ Definitive Proxy Statement permitted |
|
| May 31, 2018 |
Exhibit 1.01 Ultralife Corporation Conflict Minerals Report for the Reporting Period from January 1, 2017 to December 31, 2017 Introduction Ultralife Corporation has prepared this Conflict Minerals Report (“Report”) for the reporting period from January 1, 2017 to December 31, 2017, as required by Rule 13p-1 under the Securities Exchange Act of 1934 (the "Rule"). Terms used and not defined in this |
|
| May 31, 2018 |
ULBI / Ultralife Corp. FORM SD UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report Ultralife Corporation (Exact name of Registrant as specified in its charter) Delaware (Jurisdiction of incorporation or organization) 000-20852 (Commission file number) 2000 Technology Parkway, Newark, New York 14513 (Address of principal executive offices) Philip A. Fain 315-332-7100 (Nam |
|
| May 3, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2018 (Date of Report) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer Identification No.) 2000 Technolo |
|
| May 3, 2018 |
Ultralife Corporation Reports First Quarter Results Exhibit 99.1 Company Contact: Ultralife Corporation Philip A. Fain (315) 210-6110 [email protected] Investor Relations Contact: LHA Jody Burfening (212) 838-3777 [email protected] Ultralife Corporation Reports First Quarter Results NEWARK, N.Y. – May 3, 2018 - Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.4 million on revenue of $23.1 million for the first quarter ended April |
|
| May 3, 2018 |
ULBI / Ultralife Corp. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarter Ended April 1, 2018 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-27460 ULTRALIFE CORPORAT |
|
| April 26, 2018 |
ULBI / Ultralife Corp. FORM 10-K/A (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) /X/ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 OR / / Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0 |
|
| February 9, 2018 |
ULBI / Ultralife Corp. / DIMENSIONAL FUND ADVISORS LP - SCHEDULE 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ULTRALIFE CORP (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule |
|
| February 8, 2018 |
ULBI / Ultralife Corp. / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G (Passive Investment) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Ultralife Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 8, 2018 |
Ultralife Corporation Reports Fourth Quarter Results ex104618.htm Exhibit 99.1 Company Contact: Investor Relations Contact: Ultralife Corporation LHA Philip A. Fain Jody Burfening (315) 210-6110 (212) 838-3777 [email protected] [email protected] Ultralife Corporation Reports Fourth Quarter Results NEWARK, N.Y. ? February 8, 2018 ? Ultralife Corporation (NASDAQ: ULBI) reported operating income of $2.1 million on revenue of $22.5 million for the fourth |
|
| February 8, 2018 |
Financial Statements and Exhibits, Results of Operations and Financial Condition ulbi201802078k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 8, 2018 (Date of Report) ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission File Number) (IRS Employer Identific |
|
| February 8, 2018 |
ULBI / Ultralife Corp. FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) /X/ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2017 OR / / Transition report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission file number 0-20852 ULTRALIFE COR |
|
| February 8, 2018 |
Exhibit 21 SUBSIDIARIES We have a 100% ownership interest in Ultralife Batteries (UK) LTD, incorporated in the United Kingdom. |
|
| February 8, 2018 |
ULBI / Ultralife Corp. / Wellington Trust Co NA - SEC SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5 )* Ultralife Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| February 8, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4 )* Ultralife Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 903899102 (CUSIP Number) December 29, 2017 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 8, 2017 |
Ultralife Corporation Awarded $3.9 Million Communications Systems Contract ex101670.htm Exhibit 99.1 Company Contact: Investor Relations Contact: Ultralife Corporation LHA Philip A. Fain Jody Burfening (315) 210-6110 (212) 838-3777 [email protected] [email protected] Ultralife Corporation Awarded $3.9 Million Communications Systems Contract NEWARK, N.Y. December 8, 2017 - Ultralife Corporation (NASDAQ: ULBI) has been awarded a contract valued at approximately $3.9 million |
|
| December 8, 2017 |
ulbi201712078k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of the earliest event reported) December 8, 2017 ULTRALIFE CORPORATION (Exact name of registrant as specified in its charter) Delaware 000-20852 16-1387013 (State of incorporation) (Commission |
